ProCE Banner Activity

CAPELLA: Wk 52 Results With Long-Acting SC Lenacapavir in Randomized and Nonrandomized Cohorts of Persons With Multidrug-Resistant HIV

Slideset Download
Conference Coverage
At Week 52, maintenance therapy with SC lenacapavir in combination with an optimized background regimen was associated with virologic suppression in 78% of heavily treatment–experienced persons with multidrug-resistant HIV infection.

Released: November 03, 2022

Expiration: November 02, 2023

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare